Sr. Director, US Team Lead, LORBRENA​/BRAF Lung

ROLE SUMMARY

Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI‑enabled infrastructure and the authority to accelerate medicines from discovery to delivery.

Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you, across teams, roles, and the Pfizer enterprise. Join us to make history, for patients, for their families, for the future.

• The LORBRENA/BRAF Lung Team Lead reports directly to the Franchise Lead, Precision Medicine Thoracic Franchise, and owns the continued growth of LORBRENA (including CROWN lifecycle execution) and the BRAFTOVI + MEKTOVI BRAF V600E-mutant NSCLC (lung) indication. This role requires close cross-functional coordination with the BRAFTOVI/MEKTOVI brand team to align lung-specific strategy, promotional assets, and field execution while preserving one coherent brand voice.
  
  The role requires strong leadership, collaboration, communication and decision-making skills, change agility, and a proven track record working across the broader franchise team, CMO, Medical, Market Access, Sales, Insights & Analytics, AI/Data Science partners, and agency cohorts.
• Directly own the design and execution of an AI-enabled marketing strategy, leveraging machine learning, predictive analytics and next-best-action engines to identify, prioritize and engage the right precision-medicine customers at the right moment.
• Lead the complexity of precision targeting across two biomarker-defined NSCLC populations (ALK+ and BRAF V600E-mutant) aligning brand strategy, diagnostic/testing pathways and HCP engagement so the right patients are identified and reached.
• Set a multi-year strategic vision for the lung portfolio, anticipating shifts in the ALK+ and BRAF V600E competitive landscape, evolving standards of care, and biomarker-testing dynamics, and shaping brand strategy today to protect and grow the franchise over a 3–5-year horizon.
• Partner cross-functionally with the BRAFTOVI + MEKTOVI brand team to drive the BRAF V600E-mutant NSCLC (lung) indication, coordinating lung-specific strategy, promotional review, biomarker-testing initiatives and field execution.
• Connect the patient journey, build the operating model, metrics and feedback loops that connect field sales and marketing execution directly to patients and hold both accountable to shared commercial outcomes.
• Strategize proactively with the Market Access team to anticipate and overcome payer challenges, shaping access strategy, coverage and reimbursement positioning, and value messaging so that appropriate, biomarker-driven patients can be identified and treated without access barriers.
• Elevate what we can say to our customers and when, elevate clarity, credibility and evidence base of our messaging so it lands with impact in an AI-enabled, data-saturated environment.
• Directly accountable for oversight and execution of the in-line lung portfolio and its performance, including quarterly earnings preparation, latest estimates, and operating plan.
• Develop the overall HCP and customer strategy and tactics to support appropriate utilization of the lung portfolio across both biomarker segments, grounded in precision‑medicine insight.
• Support the development and implementation of annual tactical plans that drive short‑ and long‑term HCP and patient…